Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target
Abstract
:1. Introduction
2. Mechanisms of Intracellular Aβ Generation and Enrichment
3. Intracellular Aβ Clearing by the Ubiquitin–Proteasome System
4. Intracellular Aβ Affects Pathways Involved in Cellular Stress, Plasticity, and Receptor Function
5. Impact of Intracellular Aβ on the Neuronal Architecture
6. Intracellular Aβ as Driver of Neuroinflammation
7. Intracellular Aβ as a Spreading Pathological Marker
8. Intracellular Aβ and Amyloidogenic Peptides in Viral Infections
9. Intracellular Aβ as a New Target for Therapeutic Drug Treatment
9.1. Bioactive Polyphenols
9.2. Cannabinoids
9.3. Antibodies
9.4. Other Treatments
10. Future Perspectives
Funding
Conflicts of Interest
References
- Hippius, H.; Neundörfer, G. The discovery of Alzheimer’s disease. Dialogues Clin. Neurosci. 2003, 5, 101–108. [Google Scholar] [CrossRef] [PubMed]
- Kumar, A.; Sidhu, J.; Goyal, A.; Tsao, J.W. Alzheimer Disease. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2022. [Google Scholar]
- DeTure, M.A.; Dickson, D.W. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener. 2019, 14, 32. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Serrano-Pozo, A.; Frosch, M.P.; Masliah, E.; Hyman, B.T. Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 2011, 1, a006189. [Google Scholar] [CrossRef] [PubMed]
- Selkoe, D.J.; Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 2016, 8, 595–608. [Google Scholar] [CrossRef] [PubMed]
- Zhao, J.; Liu, X.; Xia, W.; Zhang, Y.; Wang, C. Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease. Front. Mol. Neurosci. 2020, 13, 137. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.F.; Xu, T.H.; Yan, Y.; Zhou, Y.R.; Jiang, Y.; Melcher, K.; Xu, H.E. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 2017, 38, 1205–1235. [Google Scholar] [CrossRef] [PubMed]
- Olsson, F.; Schmidt, S.; Althoff, V.; Munter, L.M.; Jin, S.; Rosqvist, S.; Lendahl, U.; Multhaup, G.; Lundkvist, J. Characterization of intermediate steps in amyloid beta (Aβ) production under near-native conditions. J. Biol. Chem. 2014, 289, 1540–1550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Takami, M.; Nagashima, Y.; Sano, Y.; Ishihara, S.; Morishima-Kawashima, M.; Funamoto, S.; Ihara, Y. gamma-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 2009, 29, 13042–13052. [Google Scholar] [CrossRef]
- Viola, K.L.; Klein, W.L. Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015, 129, 183–206. [Google Scholar] [CrossRef]
- Gyure, K.A.; Durham, R.; Stewart, W.F.; Smialek, J.E.; Troncoso, J.C. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 2001, 125, 489–492. [Google Scholar] [CrossRef] [PubMed]
- Knobloch, M.; Konietzko, U.; Krebs, D.C.; Nitsch, R.M. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol. Aging 2007, 28, 1297–1306. [Google Scholar] [CrossRef]
- Lord, A.; Kalimo, H.; Eckman, C.; Zhang, X.Q.; Lannfelt, L.; Nilsson, L.N. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol. Aging 2006, 27, 67–77. [Google Scholar] [CrossRef]
- Liao, F.; Zhang, T.J.; Jiang, H.; Lefton, K.B.; Robinson, G.O.; Vassar, R.; Sullivan, P.M.; Holtzman, D.M. Murine versus human apolipoprotein E4: Differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models. Acta Neuropathol. Commun. 2015, 3, 70. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wirths, O.; Multhaup, G.; Czech, C.; Blanchard, V.; Moussaoui, S.; Tremp, G.; Pradier, L.; Beyreuther, K.; Bayer, T.A. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 2001, 306, 116–120. [Google Scholar] [CrossRef]
- LaFerla, F.M.; Green, K.N.; Oddo, S. Intracellular amyloid-beta in Alzheimer’s disease. Nat. Rev. Neurosci. 2007, 8, 499–509. [Google Scholar] [CrossRef] [PubMed]
- Gouras, G.K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J.P.; Haroutunian, V.; Buxbaum, J.D.; Xu, H.; et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000, 156, 15–20. [Google Scholar] [CrossRef]
- Martin, B.L.; Schrader-Fischer, G.; Busciglio, J.; Duke, M.; Paganetti, P.; Yankner, B.A. Intracellular accumulation of beta-amyloid in cells expressing the Swedish mutant amyloid precursor protein. J. Biol. Chem. 1995, 270, 26727–26730. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Koo, E.H.; Squazzo, S.L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 1994, 269, 17386–17389. [Google Scholar] [CrossRef]
- Busciglio, J.; Gabuzda, D.H.; Matsudaira, P.; Yankner, B.A. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc. Natl. Acad. Sci. USA 1993, 90, 2092–2096. [Google Scholar] [CrossRef] [Green Version]
- Cook, D.G.; Forman, M.S.; Sung, J.C.; Leight, S.; Kolson, D.L.; Iwatsubo, T.; Lee, V.M.; Doms, R.W. Alzheimer’s A beta(1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells. Nat. Med. 1997, 3, 1021–1023. [Google Scholar] [CrossRef]
- Steffen, H. Appendicitis in childhood-an analytical study. Z Arztl. Fortbild 1977, 71, 666–668. [Google Scholar]
- Yazawa, H.; Yu, Z.X.; Takeda; Le, Y.; Gong, W.; Ferrans, V.J.; Oppenheim, J.J.; Li, C.C.; Wang, J.M. Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. FASEB J. 2001, 15, 2454–2462. [Google Scholar] [CrossRef] [PubMed]
- Nagele, R.G.; D’Andrea, M.R.; Anderson, W.J.; Wang, H.Y. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer’s disease. Neuroscience 2002, 110, 199–211. [Google Scholar] [CrossRef]
- Brewer, G.J.; Herrera, R.A.; Philipp, S.; Sosna, J.; Reyes-Ruiz, J.M.; Glabe, C.G. Age-Related Intraneuronal Aggregation of Amyloid-β in Endosomes, Mitochondria, Autophagosomes, and Lysosomes. J. Alzheimers Dis. 2020, 73, 229–246. [Google Scholar] [CrossRef] [Green Version]
- Pacheco-Quinto, J.; Clausen, D.; Pérez-González, R.; Peng, H.; Meszaros, A.; Eckman, C.B.; Levy, E.; Eckman, E.A. Intracellular metalloprotease activity controls intraneuronal Aβ aggregation and limits secretion of Aβ via exosomes. FASEB J. 2019, 33, 3758–3771. [Google Scholar] [CrossRef]
- Wesén, E.; Jeffries, G.D.M.; Matson Dzebo, M.; Esbjörner, E.K. Endocytic uptake of monomeric amyloid-β peptides is clathrin- and dynamin-independent and results in selective accumulation of Aβ(1-42) compared to Aβ(1-40). Sci. Rep. 2017, 7, 2021. [Google Scholar] [CrossRef]
- Gwon, Y.; Kam, T.I.; Kim, S.H.; Song, S.; Park, H.; Lim, B.; Lee, H.; Lee, W.; Jo, D.G.; Jung, Y.K. TOM1 Regulates Neuronal Accumulation of Amyloid-β Oligomers by FcγRIIb2 Variant in Alzheimer’s Disease. J. Neurosci. 2018, 38, 9001–9018. [Google Scholar] [CrossRef] [Green Version]
- Feng, W.; Zhang, Y.; Wang, Z.; Xu, H.; Wu, T.; Marshall, C.; Gao, J.; Xiao, M. Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance. Alzheimers Res. Ther. 2020, 12, 125. [Google Scholar] [CrossRef] [PubMed]
- Kress, B.T.; Iliff, J.J.; Xia, M.; Wang, M.; Wei, H.S.; Zeppenfeld, D.; Xie, L.; Kang, H.; Xu, Q.; Liew, J.A.; et al. Impairment of paravascular clearance pathways in the aging brain. Ann. Neurol. 2014, 76, 845–861. [Google Scholar] [CrossRef] [PubMed]
- Peng, W.; Achariyar, T.M.; Li, B.; Liao, Y.; Mestre, H.; Hitomi, E.; Regan, S.; Kasper, T.; Peng, S.; Ding, F.; et al. Suppression of glymphatic fluid transport in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 2016, 93, 215–225. [Google Scholar] [CrossRef] [Green Version]
- Iliff, J.J.; Chen, M.J.; Plog, B.A.; Zeppenfeld, D.M.; Soltero, M.; Yang, L.; Singh, I.; Deane, R.; Nedergaard, M. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J. Neurosci. 2014, 34, 16180–16193. [Google Scholar] [CrossRef] [Green Version]
- Gong, B.; Radulovic, M.; Figueiredo-Pereira, M.E.; Cardozo, C. The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer’s Disease and Spinal Cord Injury. Front. Mol. Neurosci. 2016, 9, 4. [Google Scholar] [CrossRef] [Green Version]
- Taylor, R.C.; Dillin, A. Aging as an event of proteostasis collapse. Cold Spring Harb. Perspect. Biol. 2011, 3, a004440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suryadinata, R.; Roesley, S.N.; Yang, G.; Sarčević, B. Mechanisms of generating polyubiquitin chains of different topology. Cells 2014, 3, 674–689. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kumar, D.; Kumar, P. Integrated Mechanism of Lysine 351, PARK2, and STUB1 in AβPP Ubiquitination. J. Alzheimers Dis. 2019, 68, 1125–1150. [Google Scholar] [CrossRef]
- Wang, H.; Saunders, A.J. The role of ubiquitin-proteasome in the metabolism of amyloid precursor protein (APP): Implications for novel therapeutic strategies for Alzheimer’s disease. Discov. Med. 2014, 18, 41–50. [Google Scholar] [PubMed]
- Thinakaran, G.; Koo, E.H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem. 2008, 283, 29615–29619. [Google Scholar] [CrossRef] [Green Version]
- Komander, D.; Clague, M.J.; Urbé, S. Breaking the chains: Structure and function of the deubiquitinases. Nat. Rev. Mol. Cell Biol. 2009, 10, 550–563. [Google Scholar] [CrossRef] [PubMed]
- Cuello, A.C.; Allard, S.; Ferretti, M.T. Evidence for the accumulation of Abeta immunoreactive material in the human brain and in transgenic animal models. Life Sci. 2012, 91, 1141–1147. [Google Scholar] [CrossRef] [PubMed]
- Bayer, T.A.; Wirths, O. Intracellular accumulation of amyloid-Beta—A predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease. Front. Aging Neurosci. 2010, 2, 8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Almeida, C.G.; Takahashi, R.H.; Gouras, G.K. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J. Neurosci. 2006, 26, 4277–4288. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Currais, A.; Quehenberger, O.; Armando, A.; Daugherty, D.; Maher, P.; Schubert, D. Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids. NPJ Aging Mech. Dis. 2016, 2, 16012. [Google Scholar] [CrossRef] [PubMed]
- Oren, O.; Banerjee, V.; Taube, R.; Papo, N. An Aβ42 variant that inhibits intra- and extracellular amyloid aggregation and enhances cell viability. Biochem. J. 2018, 475, 3087–3103. [Google Scholar] [CrossRef]
- Oren, O.; Ben Zichri, S.; Taube, R.; Jelinek, R.; Papo, N. Aβ42 Double Mutant Inhibits Aβ42-Induced Plasma and Mitochondrial Membrane Disruption in Artificial Membranes, Isolated Organs, and Intact Cells. ACS Chem. Neurosci. 2020, 11, 1027–1037. [Google Scholar] [CrossRef] [PubMed]
- Williams, T.L.; Serpell, L.C. Membrane and surface interactions of Alzheimer’s Aβ peptide-insights into the mechanism of cytotoxicity. FEBS J. 2011, 278, 3905–3917. [Google Scholar] [CrossRef]
- Hansson Petersen, C.A.; Alikhani, N.; Behbahani, H.; Wiehager, B.; Pavlov, P.F.; Alafuzoff, I.; Leinonen, V.; Ito, A.; Winblad, B.; Glaser, E.; et al. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc. Natl. Acad. Sci. USA 2008, 105, 13145–13150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malishev, R.; Nandi, S.; Śmiłowicz, D.; Bakavayev, S.; Engel, S.; Bujanover, N.; Gazit, R.; Metzler-Nolte, N.; Jelinek, R. Interactions between BIM Protein and Beta-Amyloid May Reveal a Crucial Missing Link between Alzheimer’s Disease and Neuronal Cell Death. ACS Chem. Neurosci. 2019, 10, 3555–3564. [Google Scholar] [CrossRef]
- Cardoso, S.M.; Proença, M.T.; Santos, S.; Santana, I.; Oliveira, C.R. Cytochrome c oxidase is decreased in Alzheimer’s disease platelets. Neurobiol. Aging 2004, 25, 105–110. [Google Scholar] [CrossRef]
- Umeda, T.; Tomiyama, T.; Sakama, N.; Tanaka, S.; Lambert, M.P.; Klein, W.L.; Mori, H. Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J. Neurosci. Res. 2011, 89, 1031–1042. [Google Scholar] [CrossRef]
- Bhat, A.H.; Dar, K.B.; Anees, S.; Zargar, M.A.; Masood, A.; Sofi, M.A.; Ganie, S.A. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. Biomed. Pharmacother. 2015, 74, 101–110. [Google Scholar] [CrossRef]
- Huang, L.; McClatchy, D.B.; Maher, P.; Liang, Z.; Diedrich, J.K.; Soriano-Castell, D.; Goldberg, J.; Shokhirev, M.; Yates, J.R.; Schubert, D.; et al. Intracellular amyloid toxicity induces oxytosis/ferroptosis regulated cell death. Cell Death Dis. 2020, 11, 828. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, K.; Ueta, Y.; Wang, L.; Yamamoto, R.; Inoue, N.; Inokuchi, K.; Aiba, A.; Yonekura, H.; Kato, N. Suppression of a neocortical potassium channel activity by intracellular amyloid-β and its rescue with Homer1a. J. Neurosci. 2011, 31, 11100–11109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, F.; Zhang, Y.; Wang, L.; Sun, P.; Luo, X.; Ishigaki, Y.; Sugai, T.; Yamamoto, R.; Kato, N. Improvement of spatial learning by facilitating large-conductance calcium-activated potassium channel with transcranial magnetic stimulation in Alzheimer’s disease model mice. Neuropharmacology 2015, 97, 210–219. [Google Scholar] [CrossRef] [PubMed]
- Minicucci, J.; Alfond, M.; Demuro, A.; Gerberry, D.; Latulippe, J. Quantifying the dose-dependent impact of intracellular amyloid beta in a mathematical model of calcium regulation in xenopus oocyte. PLoS ONE 2021, 16, e0246116. [Google Scholar] [CrossRef] [PubMed]
- Demuro, A.; Parker, I. Cytotoxicity of intracellular aβ42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by stimulated production of inositol trisphosphate. J. Neurosci. 2013, 33, 3824–3833. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Floresco, S.B. The nucleus accumbens: An interface between cognition, emotion, and action. Annu. Rev. Psychol. 2015, 66, 25–52. [Google Scholar] [CrossRef]
- Schoenbaum, G.; Setlow, B. Lesions of nucleus accumbens disrupt learning about aversive outcomes. J. Neurosci. 2003, 23, 9833–9841. [Google Scholar] [CrossRef] [Green Version]
- Pavuluri, M.; Volpe, K.; Yuen, A. Nucleus Accumbens and Its Role in Reward and Emotional Circuitry: A Potential Hot Mess in Substance Use and Emotional Disorders. AIMS Neurosci. 2017, 4, 52–70. [Google Scholar] [CrossRef]
- D’Amelio, M.; Rossini, P.M. Brain excitability and connectivity of neuronal assemblies in Alzheimer’s disease: From animal models to human findings. Prog. Neurobiol. 2012, 99, 42–60. [Google Scholar] [CrossRef] [PubMed]
- Wilson, E.N.; Abela, A.R.; Do Carmo, S.; Allard, S.; Marks, A.R.; Welikovitch, L.A.; Ducatenzeiler, A.; Chudasama, Y.; Cuello, A.C. Intraneuronal Amyloid Beta Accumulation Disrupts Hippocampal CRTC1-Dependent Gene Expression and Cognitive Function in a Rat Model of Alzheimer Disease. Cereb. Cortex 2017, 27, 1501–1511. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qi, Y.; Klyubin, I.; Harney, S.C.; Hu, N.; Cullen, W.K.; Grant, M.K.; Steffen, J.; Wilson, E.N.; Do Carmo, S.; Remy, S.; et al. Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: Rapid reversal by anti-Aß agents. Acta Neuropathol. Commun. 2014, 2, 175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ochiishi, T.; Kaku, M.; Kiyosue, K.; Doi, M.; Urabe, T.; Hattori, N.; Shimura, H.; Ebihara, T. New Alzheimer’s disease model mouse specialized for analyzing the function and toxicity of intraneuronal Amyloid β oligomers. Sci. Rep. 2019, 9, 17368. [Google Scholar] [CrossRef]
- Cruz, E.; Kumar, S.; Yuan, L.; Arikkath, J.; Batra, S.K. Intracellular amyloid beta expression leads to dysregulation of the mitogen-activated protein kinase and bone morphogenetic protein-2 signaling axis. PLoS ONE 2018, 13, e0191696. [Google Scholar] [CrossRef]
- Wang, C.; Iashchishyn, I.A.; Pansieri, J.; Nyström, S.; Klementieva, O.; Kara, J.; Horvath, I.; Moskalenko, R.; Rofougaran, R.; Gouras, G.; et al. S100A9-Driven Amyloid-Neuroinflammatory Cascade in Traumatic Brain Injury as a Precursor State for Alzheimer’s Disease. Sci. Rep. 2018, 8, 12836. [Google Scholar] [CrossRef] [PubMed]
- Currais, A.; Fischer, W.; Maher, P.; Schubert, D. Intraneuronal protein aggregation as a trigger for inflammation and neurodegeneration in the aging brain. FASEB J. 2017, 31, 5–10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Welikovitch, L.A.; Do Carmo, S.; Maglóczky, Z.; Malcolm, J.C.; Lőke, J.; Klein, W.L.; Freund, T.; Cuello, A.C. Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proc. Natl. Acad. Sci. USA 2020, 117, 6844–6854. [Google Scholar] [CrossRef] [Green Version]
- Wilson, E.N.; Do Carmo, S.; Iulita, M.F.; Hall, H.; Austin, G.L.; Jia, D.T.; Malcolm, J.C.; Foret, M.K.; Marks, A.R.; Butterfield, D.A.; et al. Microdose Lithium NP03 Diminishes Pre-Plaque Oxidative Damage and Neuroinflammation in a Rat Model of Alzheimer’s-like Amyloidosis. Curr. Alzheimer. Res. 2018, 15, 1220–1230. [Google Scholar] [CrossRef]
- von Saucken, V.E.; Jay, T.R.; Landreth, G.E. The effect of amyloid on microglia-neuron interactions before plaque onset occurs independently of TREM2 in a mouse model of Alzheimer’s disease. Neurobiol. Dis. 2020, 145, 105072. [Google Scholar] [CrossRef]
- Rivest, S. TREM2 enables amyloid β clearance by microglia. Cell Res. 2015, 25, 535–536. [Google Scholar] [CrossRef] [Green Version]
- Okazawa, H. Intracellular amyloid hypothesis for ultra-early phase pathology of Alzheimer’s disease. Neuropathology 2021, 41, 93–98. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, H.; Homma, H.; Fujita, K.; Kondo, K.; Yamada, S.; Jin, X.; Waragai, M.; Ohtomo, G.; Iwata, A.; Tagawa, K.; et al. YAP-dependent necrosis occurs in early stages of Alzheimer’s disease and regulates mouse model pathology. Nat. Commun. 2020, 11, 507. [Google Scholar] [CrossRef] [PubMed]
- Olsson, T.T.; Klementieva, O.; Gouras, G.K. Prion-like seeding and nucleation of intracellular amyloid-β. Neurobiol. Dis. 2018, 113, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Gouras, G.K.; Tampellini, D.; Takahashi, R.H.; Capetillo-Zarate, E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol. 2010, 119, 523–541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Welikovitch, L.A.; Do Carmo, S.; Maglóczky, Z.; Szocsics, P.; Lőke, J.; Freund, T.; Cuello, A.C. Evidence of intraneuronal Aβ accumulation preceding tau pathology in the entorhinal cortex. Acta Neuropathol. 2018, 136, 901–917. [Google Scholar] [CrossRef]
- Sannerud, R.; Esselens, C.; Ejsmont, P.; Mattera, R.; Rochin, L.; Tharkeshwar, A.K.; De Baets, G.; De Wever, V.; Habets, R.; Baert, V.; et al. Restricted Location of PSEN2/γ-Secretase Determines Substrate Specificity and Generates an Intracellular Aβ Pool. Cell 2016, 166, 193–208. [Google Scholar] [CrossRef] [Green Version]
- Dodart, J.C.; Bales, K.R.; Gannon, K.S.; Greene, S.J.; DeMattos, R.B.; Mathis, C.; DeLong, C.A.; Wu, S.; Wu, X.; Holtzman, D.M.; et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer’s disease model. Nat. Neurosci. 2002, 5, 452–457. [Google Scholar] [CrossRef]
- Fowler, S.W.; Chiang, A.C.; Savjani, R.R.; Larson, M.E.; Sherman, M.A.; Schuler, D.R.; Cirrito, J.R.; Lesné, S.E.; Jankowsky, J.L. Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer’s disease. J. Neurosci. 2014, 34, 7871–7885. [Google Scholar] [CrossRef] [Green Version]
- Spires-Jones, T.L.; Mielke, M.L.; Rozkalne, A.; Meyer-Luehmann, M.; de Calignon, A.; Bacskai, B.J.; Schenk, D.; Hyman, B.T. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol. Dis. 2009, 33, 213–220. [Google Scholar] [CrossRef] [Green Version]
- Himeno, E.; Ohyagi, Y.; Ma, L.; Nakamura, N.; Miyoshi, K.; Sakae, N.; Motomura, K.; Soejima, N.; Yamasaki, R.; Hashimoto, T.; et al. Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann. Neurol. 2011, 69, 248–256. [Google Scholar] [CrossRef]
- Davis-Salinas, J.; Saporito-Irwin, S.M.; Cotman, C.W.; Van Nostrand, W.E. Amyloid beta-protein induces its own production in cultured degenerating cerebrovascular smooth muscle cells. J. Neurochem. 1995, 65, 931–934. [Google Scholar] [CrossRef]
- Yang, A.J.; Knauer, M.; Burdick, D.A.; Glabe, C. Intracellular A beta 1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J. Biol. Chem. 1995, 270, 14786–14792. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wozniak, M.A.; Mee, A.P.; Itzhaki, R.F. Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J. Pathol. 2009, 217, 131–138. [Google Scholar] [CrossRef] [PubMed]
- Tsai, M.C.; Cheng, W.L.; Sheu, J.J.; Huang, C.C.; Shia, B.C.; Kao, L.T.; Lin, H.C. Increased risk of dementia following herpes zoster ophthalmicus. PLoS ONE 2017, 12, e0188490. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muñoz-Quiles, C.; López-Lacort, M.; Ampudia-Blasco, F.J.; Díez-Domingo, J. Risk and impact of herpes zoster on patients with diabetes: A population-based study, 2009–2014. Hum. Vaccines Immunother. 2017, 13, 2606–2611. [Google Scholar] [CrossRef]
- Cairns, D.M.; Rouleau, N.; Parker, R.N.; Walsh, K.G.; Gehrke, L.; Kaplan, D.L. A 3D human brain-like tissue model of herpes-induced Alzheimer’s disease. Sci. Adv. 2020, 6, eaay8828. [Google Scholar] [CrossRef]
- Chen, V.C.; Wu, S.I.; Huang, K.Y.; Yang, Y.H.; Kuo, T.Y.; Liang, H.Y.; Huang, K.L.; Gossop, M. Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study. J. Clin. Psychiatry 2018, 78, 8164. [Google Scholar] [CrossRef]
- de Silva, S.M.; Mark, A.S.; Gilden, D.H.; Mahalingam, R.; Balish, M.; Sandbrink, F.; Houff, S. Zoster myelitis: Improvement with antiviral therapy in two cases. Neurology 1996, 47, 929–931. [Google Scholar] [CrossRef]
- Bubak, A.N.; Como, C.N.; Blackmon, A.M.; Frietze, S.; Mescher, T.; Jones, D.; Cohrs, R.J.; Paucek, P.; Baird, N.L.; Nagel, M.A. Varicella Zoster Virus Induces Nuclear Translocation of the Neurokinin-1 Receptor, Promoting Lamellipodia Formation and Viral Spread in Spinal Astrocytes. J. Infect. Dis. 2018, 218, 1324–1335. [Google Scholar] [CrossRef] [Green Version]
- Bubak, A.N.; Beseler, C.; Como, C.N.; Tyring, S.K.; Haley, C.; Mescher, T.; Hassell, J.E.; Cohrs, R.J.; Potter, H.; Nagel, M.A. Acute zoster plasma contains elevated amyloid, correlating with Aβ42 and amylin levels, and is amyloidogenic. J. Neurovirol. 2020, 26, 422–428. [Google Scholar] [CrossRef]
- Bubak, A.N.; Como, C.N.; Coughlan, C.M.; Johnson, N.R.; Hassell, J.E.; Mescher, T.; Niemeyer, C.S.; Mahalingam, R.; Cohrs, R.J.; Boyd, T.D.; et al. Varicella-Zoster Virus Infection of Primary Human Spinal Astrocytes Produces Intracellular Amylin, Amyloid-β, and an Amyloidogenic Extracellular Environment. J. Infect. Dis. 2020, 221, 1088–1097. [Google Scholar] [CrossRef]
- Bubak, A.N.; Beseler, C.; Como, C.N.; Coughlan, C.M.; Johnson, N.R.; Hassell, J.E.; Burnet, A.M.; Mescher, T.; Schmid, D.S.; Coleman, C.; et al. Amylin, Aβ42, and Amyloid in Varicella Zoster Virus Vasculopathy Cerebrospinal Fluid and Infected Vascular Cells. J. Infect. Dis. 2021, 223, 1284–1294. [Google Scholar] [CrossRef] [PubMed]
- Bubak, A.N.; Como, C.N.; Hassell, J.E.; Mescher, T.; Frietze, S.E.; Niemeyer, C.S.; Cohrs, R.J.; Nagel, M.A. Targeted RNA Sequencing of VZV-Infected Brain Vascular Adventitial Fibroblasts Indicates That Amyloid May Be Involved in VZV Vasculopathy. Neurol. Neuroimmunol. Neuroinflamm. 2022, 9, e1103. [Google Scholar] [CrossRef] [PubMed]
- Zambrano, A.; Solis, L.; Salvadores, N.; Cortés, M.; Lerchundi, R.; Otth, C. Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1. J. Alzheimers Dis. 2008, 14, 259–269. [Google Scholar] [CrossRef] [PubMed]
- Wozniak, M.A.; Frost, A.L.; Itzhaki, R.F. Alzheimer’s disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J. Alzheimers Dis. 2009, 16, 341–350. [Google Scholar] [CrossRef] [PubMed]
- Alvarez, G.; Aldudo, J.; Alonso, M.; Santana, S.; Valdivieso, F. Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J. Neurosci Res. 2012, 90, 1020–1029. [Google Scholar] [CrossRef]
- Ill-Raga, G.; Palomer, E.; Wozniak, M.A.; Ramos-Fernández, E.; Bosch-Morató, M.; Tajes, M.; Guix, F.X.; Galán, J.J.; Clarimón, J.; Antúnez, C.; et al. Activation of PKR causes amyloid ß-peptide accumulation via de-repression of BACE1 expression. PLoS ONE 2011, 6, e21456. [Google Scholar] [CrossRef]
- Wozniak, M.A.; Itzhaki, R.F.; Shipley, S.J.; Dobson, C.B. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci. Lett. 2007, 429, 95–100. [Google Scholar] [CrossRef]
- Shipley, S.J.; Parkin, E.T.; Itzhaki, R.F.; Dobson, C.B. Herpes simplex virus interferes with amyloid precursor protein processing. BMC Microbiol. 2005, 5, 48. [Google Scholar] [CrossRef]
- Abrahamson, E.E.; Zheng, W.; Muralidaran, V.; Ikonomovic, M.D.; Bloom, D.C.; Nimgaonkar, V.L.; D’Aiuto, L. Modeling Aβ42 Accumulation in Response to Herpes Simplex Virus 1 Infection: 2D or 3D? J. Virol. 2020, 95, e02219-20. [Google Scholar] [CrossRef]
- De Chiara, G.; Piacentini, R.; Fabiani, M.; Mastrodonato, A.; Marcocci, M.E.; Limongi, D.; Napoletani, G.; Protto, V.; Coluccio, P.; Celestino, I.; et al. Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathog. 2019, 15, e1007617. [Google Scholar] [CrossRef] [Green Version]
- Tran, D.N.; Bakx, A.T.C.M.; van Dis, V.; Aronica, E.; Verdijk, R.M.; Ouwendijk, W.J.D. No evidence of aberrant amyloid β and phosphorylated tau expression in herpes simplex virus-infected neurons of the trigeminal ganglia and brain. Brain Pathol. 2021, 2021, e13044. [Google Scholar] [CrossRef] [PubMed]
- Wong, K.H.; Riaz, M.K.; Xie, Y.; Zhang, X.; Liu, Q.; Chen, H.; Bian, Z.; Chen, X.; Lu, A.; Yang, Z. Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier. Int. J. Mol. Sci. 2019, 20, 381. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cummings, J.L.; Morstorf, T.; Zhong, K. Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimers Res. Ther. 2014, 6, 37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cummings, J. Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. Clin. Transl. Sci. 2018, 11, 147–152. [Google Scholar] [CrossRef] [PubMed]
- Becker, R.E.; Greig, N.H.; Giacobini, E. Why do so many drugs for Alzheimer’s disease fail in development? Time for new methods and new practices? J. Alzheimers Dis. 2008, 15, 303–325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anderson, R.M.; Hadjichrysanthou, C.; Evans, S.; Wong, M.M. Why do so many clinical trials of therapies for Alzheimer’s disease fail? Lancet 2017, 390, 2327–2329. [Google Scholar] [CrossRef]
- Korkina, L.G.; Afanas’ev, I.B. Antioxidant and chelating properties of flavonoids. Adv. Pharmacol. 1997, 38, 151–163. [Google Scholar] [CrossRef]
- Hanasaki, Y.; Ogawa, S.; Fukui, S. The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radic. Biol. Med. 1994, 16, 845–850. [Google Scholar] [CrossRef]
- Burda, S.; Oleszek, W. Antioxidant and antiradical activities of flavonoids. J. Agric. Food Chem. 2001, 49, 2774–2779. [Google Scholar] [CrossRef]
- Serafini, M.; Peluso, I.; Raguzzini, A. Flavonoids as anti-inflammatory agents. Proc. Nutr. Soc. 2010, 69, 273–278. [Google Scholar] [CrossRef] [Green Version]
- Maleki, S.J.; Crespo, J.F.; Cabanillas, B. Anti-inflammatory effects of flavonoids. Food Chem. 2019, 299, 125124. [Google Scholar] [CrossRef] [PubMed]
- Spagnuolo, C.; Moccia, S.; Russo, G.L. Anti-inflammatory effects of flavonoids in neurodegenerative disorders. Eur. J. Med. Chem. 2018, 153, 105–115. [Google Scholar] [CrossRef] [PubMed]
- Read, M.A. Flavonoids: Naturally occurring anti-inflammatory agents. Am. J. Pathol. 1995, 147, 235–237. [Google Scholar]
- Pang, X.; Zhang, X.; Jiang, Y.; Su, Q.; Li, Q.; Li, Z. Autophagy: Mechanisms and Therapeutic Potential of Flavonoids in Cancer. Biomolecules 2021, 11, 135. [Google Scholar] [CrossRef] [PubMed]
- Carmona-Gutierrez, D.; Zimmermann, A.; Kainz, K.; Pietrocola, F.; Chen, G.; Maglioni, S.; Schiavi, A.; Nah, J.; Mertel, S.; Beuschel, C.B.; et al. The flavonoid 4,4′-dimethoxychalcone promotes autophagy-dependent longevity across species. Nat. Commun. 2019, 10, 651. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kan, L.L.; Liu, D.; Chan, B.C.; Tsang, M.S.; Hou, T.; Leung, P.C.; Lam, C.W.; Wong, C.K. The flavonoids of Sophora flavescens exerts anti-inflammatory activity via promoting autophagy of Bacillus Calmette-Guérin-stimulated macrophages. J. Leukoc. Biol. 2020, 108, 1615–1629. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; Jiang, J.; Chao, G.; Hong, X.; Cao, H.; Zhang, S. Pure Total Flavonoids From Citrus Protect Against Nonsteroidal Anti-inflammatory Drug-Induced Small Intestine Injury by Promoting Autophagy. Front. Pharmacol. 2021, 12, 622744. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.W.; Hu, J.J.; Fu, R.Q.; Liu, X.; Zhang, Y.H.; Li, J.; Liu, L.; Li, Y.N.; Deng, Q.; Luo, Q.S.; et al. Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kγ mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells. Sci. Rep. 2018, 8, 11255. [Google Scholar] [CrossRef]
- Jiang, K.; Wang, W.; Jin, X.; Wang, Z.; Ji, Z.; Meng, G. Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells. Oncol. Rep. 2015, 33, 2711–2718. [Google Scholar] [CrossRef] [Green Version]
- Choi, S.M.; Kim, B.C.; Cho, Y.H.; Choi, K.H.; Chang, J.; Park, M.S.; Kim, M.K.; Cho, K.H.; Kim, J.K. Effects of Flavonoid Compounds on β-amyloid-peptide-induced Neuronal Death in Cultured Mouse Cortical Neurons. Chonnam. Med. J. 2014, 50, 45–51. [Google Scholar] [CrossRef] [Green Version]
- Schaffer, S.; Halliwell, B. Do polyphenols enter the brain and does it matter? Some theoretical and practical considerations. Genes Nutr. 2012, 7, 99–109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dhakal, S.; Ramsland, P.A.; Adhikari, B.; Macreadie, I. Trans-Chalcone Plus Baicalein Synergistically Reduce Intracellular Amyloid Beta (Aβ42) and Protect from Aβ42 Induced Oxidative Damage in Yeast Models of Alzheimer’s Disease. Int. J. Mol. Sci. 2021, 22, 9465. [Google Scholar] [CrossRef]
- Ochiishi, T.; Kaku, M.; Kajsongkram, T.; Thisayakorn, K. Mulberry fruit extract alleviates the intracellular amyloid-β oligomer-induced cognitive disturbance and oxidative stress in Alzheimer’s disease model mice. Genes Cells 2021, 26, 861–873. [Google Scholar] [CrossRef] [PubMed]
- Hilt, S.; Altman, R.; Kálai, T.; Maezawa, I.; Gong, Q.; Wachsmann-Hogiu, S.; Jin, L.W.; Voss, J.C. A Bifunctional Anti-Amyloid Blocks Oxidative Stress and the Accumulation of Intraneuronal Amyloid-Beta. Molecules 2018, 23, 2010. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, Y.; Zhou, H.; Yin, T.; Gong, Y.; Yuan, G.; Chen, L.; Liu, J. Quercetin-modified gold-palladium nanoparticles as a potential autophagy inducer for the treatment of Alzheimer’s disease. J. Colloid Interface Sci. 2019, 552, 388–400. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Zhao, Y.; Wang, Z.; Gong, H.; Ma, L.; Sun, D.; Yang, C.; Li, Y.; Cheng, B.; Petersen, R.B.; et al. Menadione sodium bisulfite inhibits the toxic aggregation of amyloid-β(1-42). Biochim. Biophys. Acta Gen. Subj. 2018, 1862, 2226–2235. [Google Scholar] [CrossRef] [PubMed]
- Schubert, D.; Kepchia, D.; Liang, Z.; Dargusch, R.; Goldberg, J.; Maher, P. Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease. Mol. Neurobiol. 2019, 56, 7719–7730. [Google Scholar] [CrossRef]
- Cao, C.; Li, Y.; Liu, H.; Bai, G.; Mayl, J.; Lin, X.; Sutherland, K.; Nabar, N.; Cai, J. The potential therapeutic effects of THC on Alzheimer’s disease. J. Alzheimers Dis. 2014, 42, 973–984. [Google Scholar] [CrossRef] [Green Version]
- Soto-Mercado, V.; Mendivil-Perez, M.; Jimenez-Del-Rio, M.; Velez-Pardo, C. Multi-Target Effects of the Cannabinoid CP55940 on Familial Alzheimer’s Disease PSEN1 E280A Cholinergic-Like Neurons: Role of CB1 Receptor. J. Alzheimers Dis. 2021, 82, S359–S378. [Google Scholar] [CrossRef] [PubMed]
- Calignano, A.; La Rana, G.; Loubet-Lescoulié, P.; Piomelli, D. A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Prog. Brain Res. 2000, 129, 471–482. [Google Scholar] [CrossRef] [PubMed]
- Castellano, C.; Rossi-Arnaud, C.; Cestari, V.; Costanzi, M. Cannabinoids and memory: Animal studies. Curr. Drug Targets CNS Neurol. Disord. 2003, 2, 389–402. [Google Scholar] [CrossRef] [PubMed]
- Gómez, R.; Navarro, M.; Ferrer, B.; Trigo, J.M.; Bilbao, A.; Del Arco, I.; Cippitelli, A.; Nava, F.; Piomelli, D.; Rodríguez de Fonseca, F. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J. Neurosci. 2002, 22, 9612–9617. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aizpurua-Olaizola, O.; Elezgarai, I.; Rico-Barrio, I.; Zarandona, I.; Etxebarria, N.; Usobiaga, A. Targeting the endocannabinoid system: Future therapeutic strategies. Drug Discov. Today 2017, 22, 105–110. [Google Scholar] [CrossRef] [PubMed]
- Mouhamed, Y.; Vishnyakov, A.; Qorri, B.; Sambi, M.; Frank, S.S.; Nowierski, C.; Lamba, A.; Bhatti, U.; Szewczuk, M.R. Therapeutic potential of medicinal marijuana: An educational primer for health care professionals. Drug Healthc. Patient Saf. 2018, 10, 45–66. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walsh, D.M.; Selkoe, D.J. A beta oligomers—A decade of discovery. J. Neurochem. 2007, 101, 1172–1184. [Google Scholar] [CrossRef]
- Salloway, S.; Sperling, R.; Fox, N.C.; Blennow, K.; Klunk, W.; Raskind, M.; Sabbagh, M.; Honig, L.S.; Porsteinsson, A.P.; Ferris, S.; et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 2014, 370, 322–333. [Google Scholar] [CrossRef] [Green Version]
- Marín-Argany, M.; Rivera-Hernández, G.; Martí, J.; Villegas, S. An anti-Aβ (amyloid β) single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing Aβ oligomers from the amyloid pathway. Biochem. J. 2011, 437, 25–34. [Google Scholar] [CrossRef] [Green Version]
- Esquerda-Canals, G.; Roda, A.R.; Martí-Clúa, J.; Montoliu-Gaya, L.; Rivera-Hernández, G.; Villegas, S. Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid-β Burden. J. Alzheimers Dis. 2019, 70, 1069–1091. [Google Scholar] [CrossRef] [PubMed]
- Sosna, J.; Philipp, S.; Albay, R.; Reyes-Ruiz, J.M.; Baglietto-Vargas, D.; LaFerla, F.M.; Glabe, C.G. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease. Mol. Neurodegener. 2018, 13, 11. [Google Scholar] [CrossRef] [PubMed]
- Gouras, G.K.; Almeida, C.G.; Takahashi, R.H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer’s disease. Neurobiol. Aging 2005, 26, 1235–1244. [Google Scholar] [CrossRef]
- Esquerda-Canals, G.; Martí-Clúa, J.; Roda, A.R.; Villegas, S. An Intracellular Amyloid-β/AβPP Epitope Correlates with Neurodegeneration in those Neuronal Populations Early Involved in Alzheimer’s Disease. J. Alzheimers Dis. 2017, 59, 1079–1096. [Google Scholar] [CrossRef]
- Horikoshi, Y.; Sakaguchi, G.; Becker, A.G.; Gray, A.J.; Duff, K.; Aisen, P.S.; Yamaguchi, H.; Maeda, M.; Kinoshita, N.; Matsuoka, Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem. Biophys. Res. Commun. 2004, 319, 733–737. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gallego Villarejo, L.; Bachmann, L.; Marks, D.; Brachthäuser, M.; Geidies, A.; Müller, T. Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target. Int. J. Mol. Sci. 2022, 23, 4656. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23094656
Gallego Villarejo L, Bachmann L, Marks D, Brachthäuser M, Geidies A, Müller T. Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target. International Journal of Molecular Sciences. 2022; 23(9):4656. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23094656
Chicago/Turabian StyleGallego Villarejo, Lucia, Lisa Bachmann, David Marks, Maite Brachthäuser, Alexander Geidies, and Thorsten Müller. 2022. "Role of Intracellular Amyloid β as Pathway Modulator, Biomarker, and Therapy Target" International Journal of Molecular Sciences 23, no. 9: 4656. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms23094656